Schröder, Martin http://orcid.org/0000-0001-7631-7766
Renatus, Martin
Liang, Xiaoyou
Meili, Fabian http://orcid.org/0000-0002-1726-4198
Zoller, Thomas
Ferrand, Sandrine
Gauter, Francois
Li, Xiaoyan
Sigoillot, Frederic http://orcid.org/0000-0002-8695-4838
Gleim, Scott
Stachyra, Therese-Marie http://orcid.org/0000-0003-3104-4404
Thomas, Jason R.
Begue, Damien
Khoshouei, Maryam
Lefeuvre, Peggy
Andraos-Rey, Rita
Chung, BoYee
Ma, Renate
Pinch, Benika
Hofmann, Andreas http://orcid.org/0000-0001-5450-6267
Schirle, Markus
Schmiedeberg, Niko
Imbach, Patricia
Gorses, Delphine
Calkins, Keith
Bauer-Probst, Beatrice
Maschlej, Magdalena
Niederst, Matt
Maher, Rob
Henault, Martin
Alford, John
Ahrne, Erik
Tordella, Luca
Hollingworth, Greg
Thomä, Nicolas H. http://orcid.org/0000-0003-2685-906X
Vulpetti, Anna http://orcid.org/0000-0002-3114-8679
Radimerski, Thomas
Holzer, Philipp
Carbonneau, Seth
Thoma, Claudio R.
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (884331)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_301206, CRSII5_186230)
Verein fur Krebsforschung (KFS 4980-02-2020)
Article History
Received: 12 May 2023
Accepted: 5 December 2023
First Online: 4 January 2024
Competing interests
: M.S., X.L., F.M., T.Z., S.F., F.G., X.Li, F.S., S.G., T.-M.S., J.T., D.B., P.L., R.A.-R., B.Y.C., S.C., B.P., A.H., M.Schi, N.S., D.G., K.C., B.B.-P., M.M., M.N., R.M., M.H., J.A., E.A., G.H., L.T., A.V., M.K. are employees and shareholders of Novartis Pharma. M.R., C.R.T., T.R., R.M., and P.I. are former employees of Novartis. N.H.T. receives funding from the Novartis Research Foundation and is a scientific advisory board (SAB) member of Monte Rosa Therapeutics and an advisor to Zenith Therapeutics and Ridgeline. The remaining authors declare no competing interests.